CAS No. 1644545-52-7
Batch:
Purity:99.99
Chemical Structure
Check the
Vorasidenib (AG-881)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
| IUPAC Name | 6-(6-chloro-2-pyridinyl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine | |
|---|---|---|
| CAS Number | 1644545-52-7 | |
| Molecular Formula |
C14H13ClF6N6 |
|
| Molecular Weight (MW) | 414.74 | |
| SMILES | CC(C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)NC(C)C(F)(F)F | |
| InChIKey | QCZAWDGAVJMPTA-RNFRBKRXSA-N |
Vorasidenib (AG-881) is an orally active, brain-penetrant dual inhibitor of mutated forms of isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2). By selectively targeting mutant IDH1 and IDH2 enzymes, it reduces the aberrant production of the oncometabolite D-2-hydroxyglutarate (2-HG). Lowering cellular 2-HG levels suppresses oncogenic histone and DNA hypermethylation, thereby reversing cellular differentiation arrest and inhibiting tumor cell proliferation in mutant IDH-driven malignancies. [1]
|
Concentration
Volume
Mass
|
|---|
Batch:
All in vitro solubility values are batch-tested experimental data (non-literature values).
| Solvent | Solubility & Note |
|---|---|
| DMSO |
82 mg/mL
(197.71 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO. The recommended stock concentration is 10 mM in DMSO.) |
| Ethanol | 82 mg/mL |
| Water | Insoluble |
| DMSO |
83 mg/mL
(200.12 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO. The recommended stock concentration is 10 mM in DMSO.) |
| Ethanol | 83 mg/mL |
| Water | Insoluble |
Q: Why does a DMSO stock precipitate in media/saline?
A: It is caused by unheated aqueous media (supersaturation), local solvent shock, or incorrect mixing sequence.
How to fix it?
- Preheat media/saline to 37°C.
- Mix rapidly (pipette/vortex) upon addition.
- For complex mixes, always add the aqueous phase last.
- Re-dissolve minor precipitates with a 37°C water bath and sonication (≤30 min).
- Vorasidenib (AG-881) Mechanism of Action: Mutant IDH Inhibition in Glioma Cell Research
- Vorasidenib (AG-881) Clinical Trials
- Vorasidenib (AG-881): Selectivity & Specificity
- Vorasidenib (AG-881) Working Concentration | Cell Culture | Treatment
- Vorasidenib (AG-881) Solubility in DMSO
- Vorasidenib (AG-881) Stock Solution
- Vorasidenib (AG-881) Storage
- Vorasidenib (AG-881) Stability
- Vorasidenib (AG-881) Combination Database
- Vorasidenib (AG-881) Molecular Weight
- Vorasidenib (AG-881) SMILES
- Vorasidenib (AG-881) Chemical Structure (2D and 3D)
- Vorasidenib (AG-881) IC50 for Cell-based and Cell-free Assays
- Vorasidenib (AG-881) MedChemExpress (HY-104042)? Try a better option.
- Vorasidenib (AG-881) Cayman (28462)? Try a better option.
- Vorasidenib (AG-881) Abmole (M10308)? Try a better option.
- Vorasidenib (AG-881) Sigma (AMBH303C55F9)? Try a better option.
- Vorasidenib (AG-881) SDS|MSDS
Note: Technical data last updated: Sep 1, 2026.